Loading
A phase 2 trial of Mirvetuximab soravtansine in ovarian cancer, run by AbbVie, active and no longer recruiting.
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression is a phase 2 interventional study registered as NCT06365853 by AbbVie, with 108 participants enrolled, started 2024-07-29 and due to reach its primary completion in 2027-02. Interventions recorded: Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops. Conditions listed: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/